Option Care conducted an independent Infliximab infusion safety study. Our results confirm previously published findings that home and ambulatory infusion suites (AIS) are safe settings for Infliximab administration¹. After treating 291 unique atients, representing 1,866 infusions over the course of two years, none of the infusions were associated with a severe adverse drug event.
Demonstrated industry leader providing infusion therapies to treat Chronic Inflammatory Disorders (CID)
Time-saving intake coordination
Option Care is contracted with national, regional and local payers including all state BCBS plans. Our specialists help throughout the enrollment process from insurance verification to prior authorization and billing of services. They also coordinate with patient assistance programs to minimize patient’s out of pocket expense.
Individualized care plans
Many CID infusions can be safely administered at an AIS or home. We customize chronic inflammatory treatment plans to the specific needs of each patient. Our pharmacists conduct a full case review and consult with prescribing physicians and healthcare providers as needed to ensure appropriate medication choices or suggest treatment adjustments. We adapt the established protocols to meet your requirements while helping to achieve optimal treatment outcomes.
Clinical monitoring and reporting
Specialized nurses monitor and track patients throughout the infusion treatment. Option Care notifies physicians of adverse changes in patient status and provides routine updates at intervals designated by the physician or healthcare provider.
Long-term support and education
Option Care infusion nurses counsel patients and caregivers on infusion, self-care and monitoring tools, and proper hygiene maintenance. When it comes to infusion therapy our dedication to optimal outcomes allows patients to achieve their health care goals. Option Care provides 24/7 patient support with experienced clinicians.
Sign up to receive more information and periodic updates about Option Care.